Cargando…
Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease, with a median survival of 2–3 years and variable natural history, characterized by gradual and progressive deterioration. Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication, associated with po...
Autores principales: | Naccache, Jean-Marc, Montil, Melissa, Cadranel, Jacques, Cachanado, Marine, Cottin, Vincent, Crestani, Bruno, Valeyre, Dominique, Wallaert, Benoit, Simon, Tabassome, Nunes, Hilario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458697/ https://www.ncbi.nlm.nih.gov/pubmed/30971235 http://dx.doi.org/10.1186/s12890-019-0830-x |
Ejemplares similares
-
The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population
por: Borie, Raphael, et al.
Publicado: (2013) -
Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?
por: Sesé, Lucile, et al.
Publicado: (2021) -
Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey
por: Cottin, Vincent, et al.
Publicado: (2015) -
Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial
por: Freund, Yonathan, et al.
Publicado: (2019) -
Rituximab for auto-immune alveolar proteinosis, a real life cohort study
por: Soyez, Berenice, et al.
Publicado: (2018)